Shots:

• Vertex signs a licensing agreement with CRISPR to develop & discover gene editing therapies for DMD and DM1. CRISPR to get $1B- as total deal value including $175M upfront- milestones and royalties on sales. Vertex to get exclusive WW rights for IPR of gene editing therapies including foundational CRISPR/Cas9 technology- novel endonucleases- single and double cut guide RNAs- and AAV vectors
• Vertex to take care of all cost related to research- development- manufacturing- and commercialization of products and the companies will share cost for specified guide RNA research conducted by CRISPR. CRISPR also holds an option to co-develop & co-commercialize all DM1 products in exchange of milestones and royalties at IND filling
• Additionally- Vertex acquires Exonics Therapeutics- in all stock transaction making total deal value $1B including $245M upfront and milestones for DMD and DM1 programs. Both the transactions are expected to close in Q3’19

Click here to read full press release/ article

 Ref: Vertex | Image: Vertex